- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Docetaxel use associated with significant reduction in prostate cancer death
Overview
In a new study, investigators from Brigham and Women's Hospital, a meta-analysis of five prospective randomized clinical trials (RCTs) found that adding docetaxel to standard-of-care (SOC) treatment was associated with a 70% reduction in death from prostate cancer-specific mortality (PCSM). The study was published in JAMA Network Open.
Investigators performed a meta-analysis of the RCTs evaluating SOC treatment with radiotherapy and androgen deprivation therapy or with radical prostatectomy versus SOC plus docetaxel. The final study cohort of 2,184 patients included 145 eligible patients (6.6%) across four eligible RCTs.
"Of these 145 patients, 139 had excellent performance status [PS] and were the main focus of the study. An excellent PS identifies patients who can tolerate the full course of chemotherapy and therefore benefit if the treatment proves effective," says Anthony Victor D'Amico, senior author of the study.
Among these 139 patients, SOC plus docetaxel was associated with a significant 70% reduction in PCSM and nearly halved all-cause mortality. Remarkably, this treatment regiment dropped the 10-year PCSM rate from nearly 40% to less than 10%, leading to a 10-year overall survival of 80% as compared to 60%.
Reference: Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels
Speakers
Isra Zaman
B.Sc Life Sciences, M.Sc Biotechnology, B.Ed